Publications by authors named "P De Porre"
Background: Adding apalutamide to androgen-deprivation therapy (ADT) resulted in a rapid (at 3- and 6-mo treatment) and deep prostate-specific antigen (PSA) decline (to ≤0.2 ng/ml or ≥90% from baseline), improved overall survival, reduced risk of disease progression, and prolonged health-related quality of life (HRQoL) in nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN and metastatic castration-sensitive PC (mCSPC) in TITAN.
Objective: To evaluate the association of a rapid, deep PSA decline at 3 and 6 mo achieved with the addition of apalutamide to ADT with patient-reported outcomes (PROs) in SPARTAN and TITAN.
Article Synopsis
- Niraparib (NIRA) is a selective drug that inhibits PARP1 and PARP2, important enzymes for DNA repair.
- The phase II QUEST study tested NIRA alongside other medications in men with advanced prostate cancer who had specific genetic alterations and had already undergone one treatment.
- The combination of NIRA with abiraterone acetate and prednisone showed good effectiveness and a tolerable safety profile.
Background: The phase III SPARTAN study demonstrated that apalutamide significantly improves metastasis-free survival and overall survival vs. placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). However, patients receiving apalutamide experienced falls more frequently vs.
View Article and Find Full Text PDFBackground: The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear.
Objective: To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR.
Design, Setting And Participant: COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use.